Pemgarda and Ensitrelvir

Background

Pemgarda and Ensitrelvir are a combination therapy being explored for long COVID. Pemgarda is a long-acting monoclonal antibody targeting residual SARS-CoV-2 particles, providing extended protection for immunocompromised individuals. Ensitrelvir is a novel antiviral that inhibits SARS-CoV-2 replication, preventing new viral particles from forming. This combination could help address persistent infection in patients with long COVID.

Mechanism of Action

1. Pemgarda A long-acting monoclonal antibody designed to remain in the body for 44 days, Pemgarda binds to SARS-CoV-2 particles, neutralizing them and possibly stimulating immune responses (FDA Factsheet, Biopharma Media).
2. Ensitrelvir A SARS-CoV-2 protease inhibitor that blocks viral protein assembly, effectively halting replication in infected cells (Clinical Study on Ensitrelvir).

Risks

• Pemgarda: 0.6% risk of anaphylaxis in clinical settings requiring emergency preparation (FDA Factsheet).
• Ensitrelvir: Potential interactions with liver enzymes, requiring careful patient monitoring (Clinical Study on Ensitrelvir).

Why Combination Treatments?

Combining these two drugs could reduce the chance of drug-resistant viral strains and offer comprehensive protection.

References

1. FDA Factsheet, Pemgarda
2. Clinical Study on Ensitrelvir
3. Industry Analysis, Pemgarda